A French claims cohort found no increased measured early neurodevelopmental risk with clonazepam compared with lamotrigine.
The study included 9,034 children exposed to antiseizure monotherapy, including 1,246 exposed to clonazepam. Outcomes included coded neurodevelopmental diagnoses and speech-therapy visits. Unlike valproate, clonazepam was not associated with increased risk of the studied outcomes relative to lamotrigine.
The reference was another medication-exposed group, not all unexposed pregnancies. Claims may miss diagnoses or relevant confounders, and early follow-up cannot establish the absence of later-emerging difficulties. The finding also applies to the studied monotherapy definition rather than every combination or dose. It should not be presented as proof that prenatal clonazepam has no risks. The paper supplies a reassuring null observation within defined outcomes and timing, while explicitly calling for longer follow-up.
Original analysis of the supplied journal article, identified as PMC7282331.